Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Nasopharyngeal Carcinoma 35Esophageal Squamous Cell Carcinoma 19Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Squamous Cell Carcinoma of Head and Neck 15Triple Negative Breast Neoplasms 14Breast Neoplasms 12Uterine Cervical Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 10Melanoma 10Carcinoma, Renal Cell 9Stomach Neoplasms 8Recurrence 8Head and Neck Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Advanced Solid Tumor 5Urinary Bladder Neoplasms 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Liver Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4Solid Tumor 3Nasopharyngeal Neoplasms 3

Interventions

Liver Transplantation 4Gemcitabine 4Cisplatin 4Capecitabine 4Radiosurgery 3toripalimab 2Specimen Handling 2Self Expandable Metallic Stents 2Platinum 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1Saline Solution 1Radiofrequency Ablation 1Photosensitizing Agents 1Photochemotherapy 1Pancreatic Hormones 1Optical Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Klatskin Tumor × toripalimab × Clear all
NCT06717464 2024-12-05

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
110 enrolled
Gastrointestinal

Gallbladder Neoplasms, Klatskin Tumor

NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Peking Union Medical College Hospital

Phase 2 Unknown
44 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡